Sumitomo Pharma's share price rose from the ¥1,567 range to ¥1,609 in mid-September, with increased trading volume, factors in its results and capital strengthening cited as the backdrop.
The share price rose from ¥1,567.5 to ¥1,609.5 between 14 and 18 September. Trading volume reached 4.286 million shares on 16 September, while the price rose 5.30% from the previous day to ¥1,598 on 17 September, extending the recovery amid a wide trading range.
On 11 September, a major US securities firm raised its target price to ¥2,700 while maintaining its bullish stance. In the week following the announcement, the share price moved up from the low ¥1,500s to around ¥1,600.
Results for the first quarter of the fiscal year ending March 2027 showed revenue of ¥129.5 billion, up 19.9% year on year, and profit attributable to owners of the parent of ¥17.0 billion, up 51.7%. Operating profit was ¥18.2 billion, down 10.8%.
The first-quarter summary indicated that higher sales of Orgovyx and Gemtesa in the United States drove revenue growth, while the impact of the transfer of the Asia business interest and increases in promotional and research and development expenses affected profits.
The full-year forecast for the fiscal year ending March 2027 remains unchanged at revenue of ¥540.0 billion and operating profit of ¥90.0 billion. As of 24 September, the forecast had not been revised, making progress against the forecast the next focus.
IFIS Stock Forecast reported a 1.5% decline from the previous week on 11 September, while noting a period in which a raised target price reflecting a continued bullish stance coincided with a new downside forecast.
Following the public offering, total equity rose 39.7% to ¥408.6 billion and the equity ratio attributable to owners of the parent increased to 48.4%. Liabilities declined following the repayment of long-term borrowings, with the figures showing the rebuilding of the financial base.